Mode
Text Size
Log in / Sign up
Phase 4 Completed N=100 Randomized Double-blind Treatment

Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile

Postoperative Respiratory Condition
Source: ClinicalTrials.gov NCT02243943 ↗
Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcomePrimary: Mean Lowest Saturation — 96.8; 93.3 percentage of oxygen saturation
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Suboptimal reversal of neuromuscular blockage after surgery is possibly related to unfavorable postoperative respiratory conditions and elevated pain levels. Rapid and complete reversal of neuromuscular block was not possible untill sugammadex was discovered. The investigators hyposthesise that reversal with sugammadex leads to favorable postoperative respiratory conditions and less pain compared to reversal with neostigmine.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Lowest Saturation
96.8; 93.3
SECONDARY
Pain
3.0; 3.2
SECONDARY
Sedation
1.4; 1.4

Eligibility Criteria

Inclusion Criteria

  • Age 18 years
  • - BMI < 35
  • -ASA class I- III
  • -Patients scheduled for surgery requiring general anesthesia with the use of NMBA's
  • Patients with ability to give oral and written informed consent

Exclusion Criteria

  • Failure to meet the inclusion criteria
  • -Known or suspected neuromuscular disorders impairing neuromuscular function
  • -Allergies to muscle relaxants, anesthetics or narcotics
  • A (family) history of malignant hyperthermia
  • -Women who are or may be pregnant or are currently breast feeding
  • -Contraindications for the use of neostigmine
  • Intestinal obstruction,
  • COPD GOLD 4
  • -Abnormal heart rhythm (eg. bradycardia: < 40/min);
  • -Surgery requiring neuraxial anesthesia / analgesia
  • -Preoperative cognitive dysfunction or mental disabilities
  • -Preexistent significant pulmonary disease with preoperative SpO2 < 90%
  • -Preoperative ICU treatment / intubation (ICU patient);
  • -Need for postoperative ICU treatment or ventilation;
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02243943). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search